Vistagen Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Vistagen Therapeutics

06/08/2024 13:59

* Vistagen Therapeutics Inc  VTGN.OQ   VTGN.O  is expected
to report resultson August 8 (estimated) for the period ending
June 30 2024
    * The South San Francisco California-based  company is
expected to
report revenue of $300 thousand, according to the mean estimate
from 2 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Vistagen Therapeutics
Inc is
for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vistagen
Therapeutics Inc is $12.00​, above​ its last closing price
of $3.20. ​​​

This summary was machine generated August 6 at 12:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)